^
    1d
    ACADEMY: A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC (clinicaltrials.gov)
    P2, N=38, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Oct 2027 --> Oct 2028 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    6d
    A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P1/2, N=48, Completed, Sun Yat-sen University | Not yet recruiting --> Completed | Trial completion date: Dec 2024 --> May 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    cisplatin • gemcitabine • AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    7d
    HMPL-012-SPRING-P105: Efficacy and Safety of Surufatinib Combined With Gemcitabine and Albumin-bound Paclitaxel in the Peri-operative Treatment of Pancreatic Cancer (clinicaltrials.gov)
    P2, N=29, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Trial completion date: May 2026 --> Dec 2026
    Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel • Sulanda (surufatinib)
    7d
    HMPL-012-SPRING-OS101: Surufatinib in Patients With Osteosarcoma and Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=47, Active, not recruiting, Sun Yat-sen University | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Dec 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Sulanda (surufatinib)
    7d
    HMPL-012-SPRING-NEN109: A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors (clinicaltrials.gov)
    P2, N=6, Terminated, Changhai Hospital | N=100 --> 6 | Trial completion date: Nov 2026 --> Jun 2026 | Not yet recruiting --> Terminated | Trial primary completion date: Nov 2026 --> Jun 2026; This investigator-initiated study closed to recruitment early due to slower-than-anticipated patient accrual.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Sulanda (surufatinib)
    8d
    Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance (clinicaltrials.gov)
    P2, N=59, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Apr 2026 --> Sep 2026 | Trial primary completion date: Apr 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • Cyramza (ramucirumab) • pemetrexed
    8d
    Plasma PlGF as a Potential Biomarker in Ramucirumab-Based Second-Line Therapy for Advanced Gastroesophageal Adenocarcinoma: Exploratory Biomarker Analysis from the Phase II Part of the RAMIRIS Trial. (PubMed, Int J Cancer)
    The phase II RAMIRIS trial compared RAM plus paclitaxel with RAM plus FOLFIRI (5-fluororuracil, leucovorin and irinotecan) in this setting...Elevated PlGF-particularly its early increase during RAM-based therapy-was associated with shortened survival and may represent a dynamic marker of unfavorable prognosis in advanced gastric/GEJ adenocarcinoma. Given the exploratory nature of this analysis, these findings should be considered hypothesis-generating and require validation in independent biomarker-driven studies.
    P2 data • Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    paclitaxel • 5-fluorouracil • Cyramza (ramucirumab) • irinotecan • leucovorin calcium
    13d
    Pembrolizumab Plus Ramucirumab in Metastatic Gastric Cancer (clinicaltrials.gov)
    P2, N=26, Completed, Samsung Medical Center | Recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Cyramza (ramucirumab)
    13d
    Impact of prior nivolumab on treatment outcomes of taxane plus ramucirumab in advanced gastric cancer. (PubMed, Jpn J Clin Oncol)
    Prior ICI exposure may not significantly affect the efficacy or safety of subsequent taxane plus RAM therapy.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Opdivo (nivolumab) • Cyramza (ramucirumab) • oxaliplatin
    14d
    SYSKY-2023-1262-02: Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=32, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Trial completion date: Sep 2026 --> Sep 2028 | Trial primary completion date: Mar 2026 --> Mar 2028
    Trial completion date • Trial primary completion date
    |
    AiTan (rivoceranib) • Teysuno (gimeracil/oteracil/tegafur) • AiRuiLi (adebrelimab)
    14d
    24-Week Recurrence Rate of Gout Following Firsekibart Treatment (clinicaltrials.gov)
    P=N/A, N=264, Not yet recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New trial • Real-world evidence
    |
    Jin Beixin (firsekibart)
    15d
    Lung-MAP Sub-Study: Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) (clinicaltrials.gov)
    P2, N=66, Recruiting, SWOG Cancer Research Network | Trial completion date: May 2027 --> Jun 2028 | Trial primary completion date: May 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • MET (MET proto-oncogene, receptor tyrosine kinase)
    |
    EGFR mutation • MET amplification
    |
    Tagrisso (osimertinib) • Cyramza (ramucirumab) • Tabrecta (capmatinib)